为了保障包头东宝生物技术股份有限公司（下称"公司"）董事和高级管理 人员依法履行职责，有效调动董事和高级管理人员的工作积极性，提高经营效率， 根据《中华人民共和国公司法》、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》、《上市公司治理准则》、《上市公司独立董 事管理办法》等法律法规及《包头东宝生物技术股份有限公司章程》的有关规定， 结合公司实际情况，特制定本办法。 包头东宝生物技术股份有限公司 董事及高级管理人员薪酬管理办法 （2025 年 4 月） 第一章 总则 第一条 本办法所指董事和高级管理人员包括：公司董事、总经理、副总经 理、董事会秘书、财务总监。 第二条 公司制定本办法遵循以下原则： （一）按劳分配与责、权、利相结合的原则； 第二章 薪酬管理机构 第三条 公司董事会授权薪酬和考核委员会，负责董事和公司高级管理人员 的薪酬标准与方案考评及管理；负责审查公司董事、高级管理人员履职情况并对 其进行年度考评；公司人力资源部和财务部协助实施。 第三章 薪酬标准 第四条 董事津贴 1、独立董事津贴为每人每年人民币 10 万元； 2、外部董事津贴为每人每年人民币 3.6 万元；外部董 ...

包头东宝生物技术股份有限公司 章 程 二〇二五年四月 | ਮ | | --- | | 第一章 总 | 则 - 2 - | | | --- | --- | --- | | 第二章 | 经营宗旨和范围 - 3 - | | | 第三章 股 | 份 - 4 - | | | 第一节 股份发行 | | - 4 - | | 第二节 股份增减和回购 | | - 5 - | | 第三节 股份转让 | | - 6 - | | 第四章 | 股东和股东会 - 7 - | | | 第一节 股 东 | | - 7 - | | 第三节 股东会的一般规定 | - | 10 - | | 第四节 股东会的召集 | - | 13 - | | 第五节 股东会的提案与通知 | - | 14 - | | 第六节 股东会的召开 | - | 16 - | | 第七节 股东会的表决和决议 | - | 18 - | | 第五章 | 董事和董事会 - 23 - | | | 第一节 董事的一般规定 | - | 23 - | | 第二节 董事会 | - | 26 - | | 第三节 独立董事 | - 32 - | | | 第四节 董事会专门委员会 | - 34 - ...

包头东宝生物技术股份有限公司 独立董事 2024 年度述职报告 (任斌) 各位股东及股东代表： 本人任斌，作为包头东宝生物技术股份有限公司(以下简称"公司")独立董事， 2024 年度，严格按照《上市公司独立董事管理办法》、《深圳证券交易所上市 公司自律监管指引第 2 号——创业板上市公司规范运作》等法律法规和《公司章 程》、公司《独立董事工作制度》等规章制度的有关规定，本着客观、公正、独 立的原则及对全体股东负责的态度，勤勉尽责、独立履职，促进公司规范运作、 健康发展，维护公司、全体股东特别是中小股东的利益。现将本人 2024 年度工 作情况报告如下： 一、独立董事基本情况 2、出席董事会专门委员会、独立董事专门会议的基本情况 任斌，男，1962 年 9 月出生，中国国籍，无永久境外居留权，中国农业大 学农业推广硕士。1985 年 7 月至今，任教于内蒙古农业大学，从事科研、农业 技术推广、实践教学和创新创业教育工作，参与多项农牧业科研项目、国家重点 研发计划项目；现任公司独立董事、薪酬和考核委员会召集人、战略委员会委员。 本人作为公司董事会独立董事，未在公司担任独立董事及董事会专门委员会 委员以外的任何职 ...

第一章 总则 包头东宝生物技术股份有限公司 董事会议事规则 （2025 年 4 月） 第二章 董事会的组成及职权 第四条 董事会由 7 名董事组成，其中独立董事 3 人，职工代表董事 1 人。 第五条 董事会设董事长 1 人、可设副董事长 1 人。董事长、副董事长由董 1 事会以全体董事的过半数选举产生。 第六条 公司董事为自然人，有下列情形之一的，不能担任公司的董事： （一）无民事行为能力或者限制民事行为能力； （二）因贪污、贿赂、侵占财产、挪用财产或者破坏社会主义市场经济秩序， 被判处刑罚，或者因犯罪被剥夺政治权利，执行期满未逾 5 年，被宣告缓刑的， 自缓刑考验期满之日起未逾二年； 第一条 为了进一步规范包头东宝生物技术股份有限公司（以下简称"公司"） 董事会的议事方式和决策程序，促使董事和董事会有效地履行其职责，提高董事 会规范运作和科学决策水平，根据《中华人民共和国公司法》、《中华人民共和 国证券法》、《上市公司治理准则》和《深圳证券交易所创业板股票上市规则》 (以下简称《创业板上市规则》)、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》(以下简称《规范运作》)、《上市公 ...

包头东宝生物技术股份有限公司 独立董事 2024 年度述职报告 (高德步) 各位股东及股东代表： 本人高德步，作为包头东宝生物技术股份有限公司(以下简称"公司")第八届 董事会独立董事，2024 年度，严格按照《上市公司独立董事管理办法》、《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等法 律、法规和《公司章程》、公司《独立董事工作制度》等规章制度的有关规定， 本着客观、公正、独立的原则及对全体股东负责的态度，勤勉尽责、独立履职， 促进公司规范运作、健康发展，维护公司、全体股东特别是中小股东的利益。 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 等法律法规、规范性文件和《公司章程》、公司《独立董事工作制度》中关于独 立董事的独立性要求。 二、独立董事年度履职概况 (一)出席会议情况 1、出席股东大会、董事会的基本情况 本人履职期间，公司共召开了 2 次董事会，1 次股东大会，本人作为公司第 八届董事会独立董事，以认真勤勉的履职态度，通过现场/通讯方式亲自出席了 公司全部股东大会、董事会，没有委托出席或缺席情况。公司董事会、股东大会 的召集、召开程序符 ...

Financial Performance - The company's operating revenue for 2024 was ¥884,932,215.88, a decrease of 9.19% compared to ¥974,512,217.68 in 2023[21]. - Net profit attributable to shareholders for 2024 was ¥85,982,726.28, down 28.28% from ¥119,885,372.42 in 2023[21]. - The basic earnings per share for 2024 was ¥0.1448, reflecting a decline of 28.32% from ¥0.2020 in 2023[21]. - The total assets at the end of 2024 were ¥2,624,919,556.21, a decrease of 4.27% from ¥2,742,011,238.13 at the end of 2023[21]. - The company reported a significant drop in cash flow from operating activities, with a net amount of ¥69,131,118.11 in 2024, down 65.33% from ¥199,394,288.50 in 2023[21]. - The company achieved operating revenue of 884.93 million yuan, a year-on-year decrease of 9.19%[59]. - Net profit attributable to shareholders was 85.98 million yuan, down 28.28% year-on-year[59]. Market and Industry Trends - The company is focusing on the health and nutrition market, emphasizing the development of high-value collagen products and expanding into new application areas such as new materials[30]. - The Chinese nutritional health food retail market exceeded $37 billion in 2023, with a compound annual growth rate of 7.0% over the past three years, indicating significant growth potential[32]. - The market for health products is projected to grow at a CAGR of 6.2%, reaching $44.2 billion by 2026[33]. - The demand for anti-aging products is increasing due to a growing awareness of health and wellness among consumers, leading to a rise in collagen-based skincare products[33]. - The aging population and rising disposable income are expected to stabilize the demand for the pharmaceutical and nutrition health market[34]. - Government policies are increasingly supportive of the health industry, emphasizing food and drug safety and promoting innovation in pharmaceuticals[35]. Research and Development - The company is actively involved in research and development to innovate new products and technologies in the biotechnology sector[14]. - The company has established a dual-driven R&D model focusing on independent innovation and collaborative research with various institutions[63]. - The company has a strong focus on research and development, with platforms like the first batch of key laboratories for gelatin in China, enhancing its innovation capabilities[53]. - The number of R&D personnel increased by 13.77% from 138 in 2023 to 157 in 2024, with R&D personnel now accounting for 11.34% of the total workforce[83]. - R&D expenditure for 2024 was approximately ¥38.76 million, representing 4.38% of operating revenue, a slight increase from 4.27% in 2023[83]. Corporate Governance - The board of directors consists of 7 members, including 3 independent directors, and has held 9 meetings during the reporting period[151]. - The supervisory board has 3 members, including 1 employee representative, and has held 7 meetings in compliance with regulations[151]. - The company maintains good communication with investors through various channels, including annual performance briefings and investor interaction platforms[152]. - The company's governance practices align with legal and regulatory requirements, with no significant discrepancies noted[153]. - The company operates independently from its controlling shareholders, ensuring complete autonomy in business operations and management[154]. Strategic Initiatives - The company is focusing on developing high-quality, safe pharmaceutical and nutritional products to meet the evolving consumer demands[36]. - The company is expanding its product applications into medical fields, including the production of injectable gelatin products and materials for medical aesthetics[33]. - The company is actively pursuing international market opportunities, with steady growth in its hollow capsule export business[60]. - The company is enhancing its digital management systems to improve operational efficiency and cost control[58]. - The company plans to actively participate in domestic and international exhibitions to better understand global market dynamics and enhance customer cooperation[132]. Investment and Fundraising - The company reported a total fundraising amount of RMB 86,228.17 million, with a net amount of RMB 83,895.69 million, and a total usage of RMB 52,855.44 million, resulting in a usage ratio of 63.00%[106]. - The company has a remaining balance of RMB 40,749,521.18 in its fundraising account as of December 31, 2024, which is stored in a special fundraising account[109]. - The company has raised a total of 129,057,300.00 CNY for the "Collagen Peptide Nutritional Supplement Product Construction Project," which accounts for 32.53% of the net fundraising amount[116]. - The company plans to use part of the surplus fundraising for permanent working capital, pending approval from the board and shareholders[118]. Operational Efficiency - The company has implemented a digital transformation strategy to enhance supply chain management and cost control[66]. - The company is enhancing operational efficiency through digital system upgrades and aims to establish a comprehensive digital control system for dynamic optimization[136]. - The company has adjusted its fundraising strategy to include investment in financial products, generating a net income of CNY 1.0072 million from idle funds[125]. - The company is committed to ensuring timely and efficient decision-making to protect the rights of shareholders[186]. Employee Management - The total number of employees at the end of the reporting period was 1,385, with 518 in the parent company and 867 in major subsidiaries[197]. - The company has established a performance-oriented compensation and performance assessment policy to attract and retain talent[198]. - Training plans are tailored for different job categories, covering various aspects including corporate culture, management skills, and compliance with safety regulations[199]. - The educational background of employees showed 21 with master's degrees or above, 159 with bachelor's degrees, 548 with associate degrees, and 657 with other qualifications[197].

Financial Performance - The company's revenue for Q1 2025 was ¥188,034,307.73, a decrease of 22.23% compared to ¥241,778,598.22 in the same period last year[5] - Net profit attributable to shareholders was ¥19,044,819.05, down 26.64% from ¥25,961,526.88 year-on-year[5] - Basic earnings per share decreased to ¥0.0323, down 26.09% from ¥0.0437 in the same period last year[5] - Net profit for the period was ¥19,044,700.74, down from ¥28,081,767.64, a decrease of approximately 32.3% year-over-year[25] - Total operating revenue decreased to ¥188,034,307.73 from ¥241,778,598.22, a decline of approximately 22.2% year-over-year[24] - Total operating costs decreased to ¥165,982,769.88 from ¥209,838,876.06, representing a reduction of about 20.9% year-over-year[24] Cash Flow - The net cash flow from operating activities was -¥37,532,983.25, a significant decline of 298.94% compared to -¥9,408,089.36 in the previous year[5] - The net cash flow from investing activities was -¥7,885,034.85, a decline of 186.17% compared to ¥9,150,743.28 in the previous year[11] - The net cash flow from financing activities was -¥4,808,713.19, a decrease of 284.78% compared to ¥2,602,340.67 in the previous year, primarily due to share repurchase activities[11] - Cash inflow from operating activities totaled $132.76 million, a decrease of 2.3% from the previous period's $136.28 million[28] - Cash outflow from operating activities increased to $170.29 million, up 16.8% from $145.68 million in the prior period[29] - Net cash flow from operating activities was -$37.53 million, worsening from -$9.41 million year-over-year[29] - Cash inflow from investment activities was $941.57 million, significantly higher than $33.22 million in the previous period[29] - Cash outflow from investment activities rose to $949.46 million, compared to $24.07 million last year[29] - Net cash flow from investment activities was -$7.89 million, a decline from $9.15 million in the prior period[29] - Cash inflow from financing activities increased to $40 million, up from $3 million in the previous period[29] - Cash outflow from financing activities totaled $44.81 million, compared to $0.40 million last year[29] - Net cash flow from financing activities was -$4.81 million, a decrease from $2.60 million in the prior period[29] - The ending cash and cash equivalents balance was $447.83 million, down from $715.79 million in the previous period[29] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,592,174,782.52, a decrease of 1.25% from ¥2,624,919,556.21 at the end of the previous year[5] - Total liabilities decreased to ¥873,847,735.56 from ¥885,496,289.52, a decline of about 1.5%[22] - Non-current liabilities increased to ¥604,607,479.99 from ¥561,724,206.32, an increase of approximately 7.6%[22] - The company reported a decrease in cash and cash equivalents from 532,101,881.48 yuan to 477,954,713.78 yuan[20] - Accounts receivable increased from 206,201,924.73 yuan to 212,619,685.82 yuan, indicating a rise in credit sales[20] Shareholder Information - Total number of common shareholders at the end of the reporting period is 22,262[13] - The largest shareholder, Qingdao Guoen Technology Co., Ltd., holds 21.18% of shares, totaling 125,711,022 shares, with 88,000,000 shares pledged[13] - Hainan Bainashengyuan Technology Co., Ltd. holds 5.62% of shares, totaling 33,335,422 shares, with 23,320,000 shares pledged[13] - The top 10 shareholders collectively hold significant stakes, with the first three shareholders accounting for over 29% of total shares[13] - The total number of restricted shares at the end of the period is 3,846,150 shares, with 116,287 shares released from restriction[16] Research and Development - Research and development expenses increased by 41.41% to ¥5,722,250.85, compared to ¥4,046,567.55 in the previous year[10] - Research and development expenses increased to ¥5,722,250.85 from ¥4,046,567.55, an increase of about 41.4% year-over-year[25] Other Information - The company reported a significant increase in long-term borrowings, rising by 111.02% to ¥76,073,833.34 from ¥36,050,000.00[10] - The company recorded a profit from asset disposal of ¥10,571.31, a 103.78% increase compared to a loss of ¥279,378.71 in the previous year[10] - The company has disclosed a share repurchase plan, with further details available on the official website[18] - The report indicates that the company is actively managing its shareholder structure and financial assets to enhance shareholder value[18] - Cash flow from operating activities details not provided in the extracted data[27] - Future outlook and strategic initiatives were not detailed in the provided content[27]

Group 1 - The core viewpoint of the articles highlights the importance of share buybacks as a value management tool in the capital market, especially following the release of new policies that support stock repurchase initiatives [1] - The company Dongbao Biological Technology Co., Ltd. has actively implemented its share buyback plan, with a total repurchase amount exceeding 40 million RMB as of March 31, 2025 [1] - The share buyback plan aims to optimize incentive systems, enhance innovation culture, and maintain company value and shareholder rights, thereby boosting investor confidence [1] Group 2 - Dongbao Biological is committed to advancing its "Collagen+" strategy to build a premium collagen brand, focusing on extending the industrial chain and enhancing the value chain [2] - The company plans to deepen its development in the health industry through high-quality growth and innovation, while also improving its core competitiveness [2] - The strategic focus includes comprehensive planning across brand, market, innovation, service, investment, and management to solidify its leading position in the collagen industry [2]

Core Viewpoint - Dongbao Biological is actively promoting its share repurchase plan to enhance employee incentive mechanisms and support its strategic goals in the collagen industry [1][2] Group 1: Share Repurchase Plan - The company approved a share repurchase plan on January 3, intending to use its own and/or raised funds to buy back its A-shares through centralized bidding or other legal methods [1] - The repurchase amount is set between RMB 50 million and RMB 100 million, with a maximum repurchase price of RMB 8.00 per share [1] - As of March 31, the company has repurchased 7.348 million shares, accounting for 1.2379% of the total share capital, with a total transaction amount of RMB 40.1431 million [1] Group 2: Strategic Focus and Goals - Dongbao Biological focuses on the collagen industry, aiming to innovate and deepen the application of collagen across medical, health, food, and beauty sectors [1] - The company plans to create a vertically integrated product strategy, enhancing brand and channel collaboration to diversify and increase revenue [2] - The goal is to become a leading brand in the domestic collagen market and a comprehensive enterprise group in the health industry, emphasizing scale, platform, and brand benefits [2]

证券代码：300239 证券简称：东宝生物 公告编号：2025-021 债券代码：123214 债券简称：东宝转债 包头东宝生物技术股份有限公司 二、其他情况说明 (一)公司回购股份的时间、回购股份数量及集中竞价交易的委托时段、交易 价格等符合《深圳证券交易所上市公司自律监管指引第9号——回购股份》及公 司回购股份方案的相关规定。 1、公司未在下列期间内回购公司股份： (1)自可能对本公司证券及其衍生品种交易价格产生重大影响的重大事项发 生之日或者在决策过程中，至依法披露之日内； 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 包头东宝生物技术股份有限公司(以下简称"东宝生物"或"公司")于2025 年1月3日召开第九届董事会第八次会议、第九届监事会第七次会议，审议通过了 《关于回购公司股份方案的议案》，使用公司自有资金和/或自筹资金以集中竞 价交易方式或法律法规允许的方式回购公司已发行的人民币普通股(A股)股票， 回购的公司股份用于实施员工持股计划或股权激励。本次回购股份不低于人民币 5,000万元(含)，且不超过人民币10,00 ...